Background illustration for clinical trials search

Paid Clinical Trials Norman

Discover 568 paid clinical trials in Norman, Oklahoma. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 568

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

for

Palmoplantar Pustulosis

Location: Oklahoma City OK, Birmingham AL, Fairborn OH,

Sponsor: UCB Biopharma SRL

Sex: All

Age: 18+

Code: NCT07219420

Phase3, Recruiting

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

for

Hidradenitis Suppurativa (HS)

Location: Oklahoma City OK, Dallas TX, Saint Joseph MO,

Sponsor: Incyte Corporation

Sex: All

Age: 18+

Code: NCT06855498

Phase3, Recruiting

AngelMed Guardian® System PMA Post Approval Study

for

Acute Coronary Syndrome

Location: Oklahoma City OK, Fort Worth TX, Hammond LA, El Paso TX,

Sponsor: Angel Medical Systems

Sex: All

Age: 21+

Code: NCT05412927

Recruiting

AltaValve Early Feasibility Study Protocol

for

Mitral Regurgitation, Mitral Insufficiency,

Location: Oklahoma City OK, Plano TX, Houston TX, Memphis TN,

Sponsor: 4C Medical Technologies, Inc.

Sex: All

Age: 18+

Code: NCT03997305

Recruiting

ATLAS (AltaValve) Pivotal Trial

for

Mitral Regurgitation, Mitral Insufficiency,

Location: Oklahoma City OK, Kansas City MO, Houston TX,

Sponsor: 4C Medical Technologies, Inc.

Sex: All

Age: 18+

Code: NCT06465745

Recruiting

Evaluating a One-Year Version of the Parent-Child Assistance Program

for

Alcohol Use Disorder, Substance Use Disorders,

Location: Oklahoma City OK, Enid OK

Sponsor: University of Oklahoma

Sex: All

Age: 18+

Code: NCT06163651

Recruiting

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

for

Recurrent Lung Non-Small Cell Carcinoma,

Location: Oklahoma City OK, Lawton OK, Salina KS, Amarillo TX,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT06616584

Phase2, Phase3, Recruiting

Identification and Validation of Blood-Based Biomarkers for Early Detection of Asymptomatic Lung Cancer in High-Risk Heavy Smokers

for

Lung Cancers

Location: Oklahoma City OK

Sponsor: Everest Detection, Inc.

Sex: All

Age: 30 - 70+

Code: NCT06816121

Recruiting

Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement

for

Aortic Stenosis, Coronary Artery Disease, Coronary Stenosis

Location: Oklahoma City OK, Plano TX, Wichita KS,

Sponsor: University of British Columbia

Sex: All

Age: 0+

Code: NCT04634240

Recruiting

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

for

Anatomic Stage II Breast Cancer AJCC v8,

Location: Fort Smith AR, Salina KS, Hays KS, Topeka KS,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06058377

Phase3, Recruiting

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

for

Fallopian Tube Endometrioid Adenocarcinoma,

Location: Oklahoma City OK, Fort Smith AR, Joplin MO,

Sponsor: NRG Oncology

Sex: All

Age: 18+

Code: NCT06580314

Phase3, Recruiting

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors

for

Advanced or Metastatic Solid Tumors

Location: Oklahoma City OK, Houston TX, San Antonio TX,

Sponsor: Day One Biopharmaceuticals, Inc.

Sex: All

Age: 18+

Code: NCT06752681

Phase1, Recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

for

Interstitial Lung Disease

Location: Oklahoma City OK, Dallas TX, Houston TX, New Orleans LA,

Sponsor: aTyr Pharma, Inc.

Sex: All

Age: 18+

Code: NCT05892614

Phase2, Recruiting

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

for

Relapsing Multiple Sclerosis

Location: Oklahoma City OK, Overland Park KS, St Louis MO,

Sponsor: TG Therapeutics, Inc.

Sex: All

Age: 18 - 65

Code: NCT05877963

Phase3, Recruiting

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

for

Advanced Solid Tumor

Location: Oklahoma City OK, Austin TX, Houston TX, San Antonio TX,

Sponsor: Exelixis

Sex: All

Age: 18+

Code: NCT05932862

Phase1, Recruiting

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

for

HNSCC, ESCC, Esophageal Adenocarcinoma, Gastric Adenocarcinoma,

Location: Oklahoma City OK, Dallas TX, Houston TX, San Antonio TX,

Sponsor: Normunity AccelCo, Inc.

Sex: All

Age: 18+

Code: NCT07182149

Phase1, Recruiting

Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency

for

Growth Hormone Deficiency (GHD)

Location: Oklahoma City OK, Fort Worth TX, Amarillo TX,

Sponsor: Lumos Pharma

Sex: All

Age: 3 - 11

Code: NCT06948214

Phase3, Recruiting

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

for

Idiopathic Pulmonary Fibrosis

Location: Oklahoma City OK, Dallas TX, Shreveport LA,

Sponsor: Mediar Therapeutics

Sex: All

Age: 40+

Code: NCT06967805

Phase2, Recruiting

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

for

Atrial Fibrillation (AF)

Location: Oklahoma City OK, Sherman TX, McKinney TX, Allen TX,

Sponsor: Anthos Therapeutics, Inc.

Sex: All

Age: 65+

Code: NCT05712200

Phase3, Recruiting

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

for

Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma,

Location: Oklahoma City OK, Wichita KS, Dallas TX, Amarillo TX,

Sponsor: Sameek Roychowdhury

Sex: All

Age: 18+

Code: NCT06906562

Phase2, Recruiting

Paid Clinical Trials Norman

Filter results

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

AngelMed Guardian® System PMA Post Approval Study

AltaValve Early Feasibility Study Protocol

ATLAS (AltaValve) Pivotal Trial

Interested in new trials?

Evaluating a One-Year Version of the Parent-Child Assistance Program

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Identification and Validation of Blood-Based Biomarkers for Early Detection of Asymptomatic Lung Cancer in High-Risk Heavy Smokers

Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors

Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations